No material trading signal. The inducement grants are standard for hiring new employees and represent minimal dilution. Monitor upcoming quarterly results for commercial progress of PEDMARK/PEDMARQSI.
Price Chart
Executive Summary
Fennec Pharmaceuticals filed an 8-K reporting the grant of stock options to purchase 50,000 common shares to three new non-executive employees as inducement awards under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $9.75 per share, a ten-year term, and vest over three years. This is a routine compensatory arrangement with no material financial impact.
Key Facts
- Compensation Committee approved grants on May 11, 2026, with a grant date of May 18, 2026.
- Options to purchase an aggregate of 50,000 common shares were granted to three new non-executive employees.
- Exercise price is $9.75 per share, equal to the closing price on March 15, 2026.
- Options vest over three years: one-third on the first anniversary, then monthly over 24 months.
- Grants were made under the 2026 Equity Inducement Plan, used exclusively for new hires.
Financial Impact
50,000 options at $9.75 strike price; potential dilution of approximately 0.15% of outstanding shares (based on $338M market cap and $9.75 price implying ~34.7M shares outstanding).
Risk Factors
- Minimal dilution from option exercises over time.
- No change to business fundamentals or commercial outlook.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-063271 |
| Document: fencf-20260518xex99d1.htm | 0001104659-26-063271 |
| Document: 0001104659-26-063271-index-headers.html | 0001104659-26-063271 |
| Document: 0001104659-26-063271-index.html | 0001104659-26-063271 |
| Document: 0001104659-26-063271.txt | 0001104659-26-063271 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | SC 13G/A | $10.27 | awaiting T+60 | — | $10.30 (+0.29%) |
Aug 31, 2026 8w ago | Insider Cluster | $12.03 | awaiting T+60 | — | $10.30 (−14.38%) |
Aug 31, 2026 8w ago | Insider Cluster | $12.03 | awaiting T+60 | — | $10.30 (−14.38%) |
Aug 11, 2026 11w ago | Press Release | $12.78 | awaiting T+60 | — | $10.30 (−19.41%) |
Jun 15, 2026 19w ago | Press Release | $9.19 $11.65 | ▲ +26.77% | ▲ +25.77% | $10.30 (+12.08%) |
May 22, 2026 22w ago | 8-K | $9.89 $11.87 | ▲ +20.02% | ▲ +17.30% | $10.30 (+4.15%) |
May 18, 2026 23w ago | 8-K | $9.76 $12.06 | ▲ +23.57% | ▲ +17.28% | $10.30 (+5.53%) |
May 14, 2026 23w ago | Press Release | $9.24 $10.94 | ▲ +18.40% | ▲ +14.81% | $10.30 (+11.47%) |
May 7, 2026 24w ago | Press Release | $6.90 $9.59 | ▲ +38.99% | ▲ +35.15% | $10.30 (+49.28%) |
Apr 28, 2026 25w ago | 8-K | $6.26 $9.99 | ▲ +59.58% | ▲ +55.47% | $10.30 (+64.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers